Abstract
BackgroundSecukinumab (SEC), a fully human anti–IL-17A monoclonal antibody, has significant efficacy in the treatment of moderate-to-severe psoriasis (Ps) and psoriatic arthritis (PsA), with a favourable safety profile. The Corrona Psoriasis...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have